Abstract: The present invention relates to a molecule for use in the treatment and/or prevention of viral infections caused by highly pathogenic coronaviruses, including Severe Acute Respiratory syndrome Coronavirus 2 (SARS-COV-2), or variants thereof, Severe Acute Respiratory syndrome Coronavirus ((SARS)-COV) and sarbecoviruses, said molecule being a mannose binding lectin (MBL) polypeptide, or a functional fragment, derivative, mutein or variant thereof, or an homologue having a percentage of identity with MBL polypeptide of at least 50, 60, 70, 80 or 90%, preferably for use in the treatment and/or prevention of 2019 Coronavirus disease (COVID-19).

Abstract: The present invention refers to an in-vitro or ex vivo method for the prognosis of a Coronavirus disease and/or for the monitoring of the efficacy of a therapeutic treatment of a Coronavirus disease having the steps of: a) detecting and/or measuring the amount of the protein PTX3 or of fragments thereof or of the polynucleotide coding for the protein or of fragments thereof in an isolated biological sample obtained from the subject Preferably the method further includes—the step: b) comparing the same with a proper control.

Abstract: Disclosed is the use of Serum Amyloid P component (SAP) polypeptides for the treatment of Eurotiomycetes fungi infections, in particular for aspergillosis and invasive aspergillosis, alone or in combination with pentraxin-3 (PTX3) polypeptides.

Abstract: The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.

Abstract: The present invention refers to a stably or transiently IL-1R8 deficient isolated human cell, being a natural killer (NK) cell or T cell and to their medical use, preferably in the treatment of tumours and infections.

Abstract: The present invention refers to an antibody able to recognize and bind to an epitope comprised in a sequence of human Migration Stimulating Factor (MSF), and that doesn't recognize and bind human Fibronectin 1 (hFn1) and to uses in diagnostic methods and therapy.

Abstract: The present invention relates to a diagnostic test for inflammatory endothelial dysfunctions in pregnant women. Particularly, the present invention relates to a method of diagnosing or evaluating the risk of contracting an inflammatory endothelial dysfunction of the maternal compartment comprising the following steps: a) detecting the plasma levels of long pentraxin PTX3 in blood samples taken from a pregnant woman; b) comparing the PTX3 plasma level data, obtained according to step a), with statistically significant PTX3 plasma level data of normal pregnant population.

Abstract: A permanent magnet rotor (3) for a rotary electric machine (1) comprises a rotor body (10) having a rotation axis (A) and a plurality of radial magnets (4), wherein the magnets (4) exhibit a head portion (5) located in proximity to an external surface (30) of the rotor body (10) and a base portion (6) facing towards the rotation axis (A). The base portion (6) of each magnet (4) has a width smaller than a width of the head portion (5).

Abstract: A permanent magnet rotor (3) for a rotary electric machine (1) comprises a rotor body (10) having a rotation axis (A) and a plurality of radial magnets (4), wherein the magnets (4) exhibit a head portion (5) located in proximity to an external surface (30) of the rotor body (10) and a base portion (6) facing towards the rotation axis (A). The base portion (6) of each magnet (4) has a width smaller than a width of the head portion (5).

Abstract: Provided herein are methods for treating certain conditions, including fibrosis, inflammatory, and autoimmune conditions, with conjugated compounds having Toll-like receptor modulatory activity.

Abstract: The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample.

Abstract: A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method.

Abstract: The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

Abstract: The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

Abstract: Pharmaceutical compositions are described containing a long pentraxin PTX3, particularly human PTX3, for the therapy of infectious and inflammatory or tumor diseases; expression vectors containing cDNA coding for PTX3; recombinant host cells transfected with such vectors; a method for producing substantial amounts of PTX3 involving the culturing of such cells, and the use of said vectors in the gene therapy of tumors.

Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.

Abstract: Devices and systems are provided which may be used to navigate and communicate while diving in dive sites and improve the safety of the diving experience. For example, in certain embodiments, a diver area system is provided which utilizes virtual underwater information to provide the user with their location, the location of other divers (or “buddies”), and/or location of a surface object (e.g., a dive boat). In certain embodiments, the devices and systems disclosed herein may provide user with their location relative to one or more buddies. The user can thus navigate intelligently throughout the dive site and track the location of their buddies which can improve dive safety and/or efficiency. Additionally, the user can communicate with one or more buddy divers and/or surface-based objects and individuals using embodiments of the disclosure.

Abstract: The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

Abstract: The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling.

Abstract: The use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives is described for the preparation of medicament which inhibits the biological activity of the growth factor FGF-2, useful for the prevention and treatment of diseases brought about by an altered activation of said growth factor FGF-2.